184 related articles for article (PubMed ID: 37932413)
1. Prognostic value and immune landscapes of immunogenic cell death-associated lncRNAs in lung adenocarcinoma.
Shu K; Cai C; Chen W; Ding J; Guo Z; Wei Y; Zhang W
Sci Rep; 2023 Nov; 13(1):19151. PubMed ID: 37932413
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma.
Sun D; Zhang C
Oncol Res; 2023; 31(5):753-767. PubMed ID: 37547766
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value and immune landscapes of immunogenic cell death-related lncRNAs in hepatocellular carcinoma.
Chen W; Shu K; Cai C; Ding J; Zhang X; Zhang W; Wang K
Biosci Rep; 2023 Sep; 43(9):. PubMed ID: 37584192
[TBL] [Abstract][Full Text] [Related]
4. Construction and validation of a model based on immunogenic cell death-associated lncRNAs to predict prognosis and direct therapy for kidney renal clear cell carcinoma.
Cai C; Shu K; Chen W; Ding J; Guo Z; Wei Y; Zhang W
Aging (Albany NY); 2023 Jun; 15(12):5304-5338. PubMed ID: 37379129
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib metabolism-related lncRNAs for the prediction of prognosis, tumor microenvironment and drug sensitivity in lung adenocarcinoma.
Guo Z; Zhang X; Yang D; Hu Z; Wu J; Zhou W; Wu S; Zhang W
Sci Rep; 2024 May; 14(1):10348. PubMed ID: 38710798
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value and immune landscapes of anoikis-associated lncRNAs in lung adenocarcinoma.
Wu B; Zhang X; Feng N; Guo Z; Gao L; Wan Z; Zhang W
Aging (Albany NY); 2024 Feb; 16(3):2273-2298. PubMed ID: 38319706
[TBL] [Abstract][Full Text] [Related]
7. Novel immunogenic cell death-related risk signature to predict prognosis and immune microenvironment in lung adenocarcinoma.
Li Q; Tang Y; Wang T; Zhu J; Zhou Y; Shi J
J Cancer Res Clin Oncol; 2023 Jan; 149(1):307-323. PubMed ID: 36575346
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a prognosis prediction model for lung squamous cell carcinoma related to PET/CT: basing on immunogenic cell death-related lncRNA.
Han Y; Dong Z; Xing Y; Zhan Y; Zou J; Wang X
BMC Pulm Med; 2023 Dec; 23(1):511. PubMed ID: 38102594
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
[TBL] [Abstract][Full Text] [Related]
10. Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma.
Xu Y; Tao T; Li S; Tan S; Liu H; Zhu X
Front Genet; 2022; 13():975905. PubMed ID: 36313456
[No Abstract] [Full Text] [Related]
11. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
[TBL] [Abstract][Full Text] [Related]
12. Construction of 11 metabolic-related lncRNAs to predict the prognosis in lung adenocarcinoma.
Jiang W; Xu Z; Huang L; Qin F; Yuan L; Sun Y; Qin J; Deng K; Zheng T; Long X; Li S
BMC Med Genomics; 2023 Dec; 16(1):330. PubMed ID: 38110999
[TBL] [Abstract][Full Text] [Related]
13. M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma.
Pan J; Huang Z; Lin H; Cheng W; Lai J; Li J
BMC Cancer; 2022 Nov; 22(1):1132. PubMed ID: 36333719
[TBL] [Abstract][Full Text] [Related]
14. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
[TBL] [Abstract][Full Text] [Related]
15. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
16. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma.
Liu J; Liu Q; Shen H; Liu Y; Wang Y; Wang G; Du J
Front Genet; 2022; 13():838624. PubMed ID: 35928454
[TBL] [Abstract][Full Text] [Related]
17. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
18. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.
Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L
Aging (Albany NY); 2024 Jun; 16():. PubMed ID: 38862217
[TBL] [Abstract][Full Text] [Related]
19. Identification of molecular subtypes and prognostic model to reveal immune infiltration and predict prognosis based on immunogenic cell death-related genes in lung adenocarcinoma.
Dong Y; Yu X; Song H; Chen Q; Zheng B; Ji X; Xu M; Liu J; Sun X; Wang Q; Ren R; Lu H
Cell Cycle; 2023; 22(23-24):2566-2583. PubMed ID: 38164943
[TBL] [Abstract][Full Text] [Related]
20. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
